- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02997371
IL-1ra Dose-range Study for Moderate-to-severe TBI Patients (IL1ra)
A Randomised Double Blind Placebo Controlled Dose-range Study Using Placebo, 1.5g and 3.0g of Intravenous Recombinant Interleukin-1 Receptor Antagonist (Anakinra) for Patients With Moderate-to-severe TBI
Traumatic brain injury (TBI) is a common condition with high degree of morbidity and mortality (Hyder et al., 2007). Current treatment paradigms for TBI focus on mitigating secondary injury and maintaining cerebral physiology (Carney et al., 2016), however, there are currently no approved drugs that target the underlying conditions for patients suffering from TBI (Bullock et al., 1999). It is increasingly recognised that the innate inflammatory response to TBI may inflict injury (Lucas et al., 2006), and one of the most prominent mediators of inflammation in the injured brain is the Interleukin-1 (IL-1) receptor pathway (Allan et al., 2005). An endogenous antagonist to IL-1, is available in recombinant form (IL-1ra, Kineret), and is known to be safe in TBI (Helmy et al., 2014).
In order to fully understand, and potentially optimize, the effect of Kineret, the investigators wish to conduct a dose-response study by giving three cohorts (n=20 per group) either placebo (isotonic saline), 1.5g or 3.0g of active substance administered intravenously in a double-blind, randomized setting. The concentrations have in previous studies not been shown to present any side-effects (Singh et al., 2014). The drug will be provided within 12 hours after trauma. The goal will be to provide a dose-response effect on the cerebral inflammatory response. As secondary goals, the investigators will assess the brain damage by measuring proteins in blood and cerebrospinal fluid, functional outcome and inflammation in the brain using positron emission tomography.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim
The hypothesis is that an increasing dose of the anti-inflammatory drug recombinant human Interleukin-1 receptor antagonist (IL-1ra, Kineret) will modulate the inflammatory state of the traumatically injured brain, which will attenuate the injurious processes that occur following TBI.
Study Design
While different doses of Anakinra have been used in trials, there is no knowledge of what constitutes an optimized concentration of the drug. To address this limitation, the current study will be a dose-response study in a double blind randomised clinical fashion, using placebo (n=20), 1.5 g ("intermediate dose") or (n=20) and 3.0 g ("high dose")(n=20) of Anakinra provided the first 48 hours (drug/placebo administered initially as 500 mg infusion bolus and later as an 1g or 2.5g infusion for 48 hours). Thus, a total of n=60 patients will be included. Sample-size analyses have indicated that the number of patients is sufficient to detect differences in the inflammatory response as gauged with cytokine measurements using cerebral microdialysis.
As surrogate markers of outcome for these patients, several protein biomarkers of brain injury and proteins of the innate immune responses will be quantified using techniques called ELISA and multiplex assay technology. The investigators also wish to use radiological techniques, such as magnetic resonance imaging to study damages in white matter tracts in the brain and positron emission tomography to assess the degree of microglial activation. All these methods will be used to assess the potential benefit of the treatment vs placebo.
By this type of study design, it will minimize bias and confounders that may influence the study.
Patient Recruitment
Patients with a clinical diagnosis of severe and moderate TBI will be identified by the research team at the daily departmental neuro-critical care unit meeting. Patients meeting the inclusion criteria will be approached for consent/assent if conscious or if next of kin is present. If not, consent will be assumed as we know Anakinra to be safe and there is likely to be a narrow therapeutic window. With the current patient load at Addenbrooke's Hospital, Cambridge, the investigators deem it possible to recruit one patient per week, thus estimating that the recruiting phase will take approximately two years to complete.
Sampling
All the sampling will be conducted during the acute phase when the patient is unconscious in the neuro-critical care unit. Microdialysis probes are sampled hourly. To assess inflammatory activity in the brain, positron emission tomography will be performed within the first week and after 2-3 weeks. Magnetic resonance imaging will be performed the first 2-3 weeks and then after 6 months. To measure the patient's adaptive immune response to brain specific proteins, specialised auto-immunisation assays will be performed on patient blood at day 1-3 following injury as well as after 2-3 weeks.
During the intensive care phase, blood and cerebrospinal fluid will be sampled twice per day (approximately 3mL per sampling time per compartment, volumes that we do not deem harmful to the patient) and will be collected together with hourly microdialysate fluid samples the first 7 days from admission. Blood will also be sampled at an outpatient clinic follow up at 6 and 12 months following injury. Patient samples will be anonymised and stored at -80degC in the Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge before analysis.
It will not to be possible to measure cytokines, the drug and biomarkers from all microdialysis samples due to volume constraints. Moreover, we believe that a temporal resolution of 6 hours is probably adequate for the brain concentration of the drug while 12 hours is sufficient in serum. APP and tau will also be measured every 6 hours. The only parameter that will be hourly analysed in microdialysis is cytokine and chemokines through a luminex panel.
Clinical Follow-up
Patients will be followed up at a clinic visit at 6 and 12 months after trauma by questionnaire survey using standardised outcome measures in neurosurgical patients including the golden standard extended Glasgow Outcome Score and Short Form 36.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Adel Helmy, MA, MB BChir, FRCS, PhD
- Phone Number: 00441223 216147
- Email: adelhelmy@cantab.net
Study Contact Backup
- Name: Eric P Thelin, MD, PhD
- Phone Number: 0046739365450
- Email: thelin.eric@gmail.com
Study Locations
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
- Cambridge University Hospital NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Suffer from a TBI, present with a Glasgow Coma Scale (GCS) of 3-13 and be deemed to be in need of neuro-critical care and intracranial monitoring for at least 72 hours.
- Be aged 18-65
- The first dose of Kineret (or placebo) must be provided within 12 hours after trauma.
Exclusion Criteria:
- Head injury unlikely to survive 5 days (radiological evidence of above as judged by clinical team, bilateral fixed and dilated pupils).
- Follow up not possible
- Not suitable for insertion of cranial access device to monitor the brain (such as bleeding complications)
- Active immunosuppression therapy (evidence of neutropenia, immunosuppression secondary to immunomodulatory medications, chemotherapy or radiation therapy in the 3 months preceding study entry)
- Severe Renal Insufficiency or End Stage Renal Disease (defined as a creatinine clearance <30 ml/min)
- Pregnancy/Nursing mothers
- Known hypersensitivity to E. coli derived products
- Administration of live vaccine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Isotonic saline administered as an injection and infusion
|
Placebo, administration as initially intravenous injection followed by a intravenous infusion
Other Names:
|
Experimental: 1.5 g Kineret
Kineret provided as a 500 mg injection followed by a 1g infusion.
|
Administration as initially intravenous injection followed by a intravenous infusion
Other Names:
|
Experimental: 3.0 g Kineret
Kineret provided as a 500 mg injection followed by a 2.5g infusion.
|
Administration as initially intravenous injection followed by a intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease of pro-inflammatory cytokines in brain extracellular fluid (ECF)
Time Frame: First 48 hours
|
Decrease of Tumor necrosis factor alpha and interferon gamma cytokines in brain ECF
|
First 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient outcome GOSe
Time Frame: 6 months and 12 months
|
Extended Glasgow Outcome Score (GOSe) assessments at 6 months and 1 year.
|
6 months and 12 months
|
Patient outcome SF36
Time Frame: 6 months and 12 months
|
Short Form - 36 (SF-36) assessments at 6 months and 1 year.
|
6 months and 12 months
|
Imaging outcome - PET-MRI
Time Frame: During the first 14 days
|
To determine degree of microglial activation globally and in the locality of the microdialysis catheter, using magnetic resonance imaging (MRI) in combination with positron emission tomography (PET) PK-11195 (an an isoquinoline carboxamide) ligand.
|
During the first 14 days
|
Imaging outcome - DTI-MRI
Time Frame: During the first 14 days
|
To determine degree of axonal injury globally and in the locality of the microdialysis catheter, using magnetic resonance imaging (MRI) in combination with diffuse tensor imaging (DTI).
|
During the first 14 days
|
Biochemical outcome - S100B
Time Frame: During the first 7 days + at 6 months and 12 months
|
Concentrations of protein biomarkers of tissue fate, S100B in serum (µg/L) twice per day as well as after 6 months and 12 months.
|
During the first 7 days + at 6 months and 12 months
|
Biochemical outcome - NF-L
Time Frame: During the first 7 days
|
Concentrations of protein biomarkers of tissue fate, Concentrations of protein biomarkers of tissue fate, Neurofilament Light (NF-L) in serum (µg/L) twice per day as well as after 6 months and 12 months.
|
During the first 7 days
|
Biochemical outcome - Tau
Time Frame: During the first 7 days
|
Concentrations of protein biomarkers of tissue fate, microtubuli associated protein tau (tau) measured in microdialysis every 6 hours.
|
During the first 7 days
|
Biochemical outcome - APP
Time Frame: During the first 7 days
|
Concentrations of protein biomarkers of tissue fate, Amyloid Precursor Protein Beta (APP) associated protein tau measured in microdialysis every 6 hours.
|
During the first 7 days
|
Biochemical outcome - Autoreactivity versus MBP
Time Frame: During the first 7 days + at 6 months and 12 months
|
Concentration of circulating T-cells with autoreactivity towards myelin basic protein (MBP) in serum.
|
During the first 7 days + at 6 months and 12 months
|
Monitoring outcome - ICP
Time Frame: First 7 days
|
Intracranial pressure (ICP, mmHg) during the neuro-critical care unit (NCCU) stay.
|
First 7 days
|
Monitoring outcome - CPP
Time Frame: First 7 days
|
Cerebral perfusion pressure (CPP, mmHg) during the NCCU stay.
|
First 7 days
|
Monitoring outcome - Cerebral Metabolism LPR
Time Frame: First 7 days
|
Cerebral metabolism, by measuring lactate:pyruvate ratio (LPR) in microdialysis.
|
First 7 days
|
Monitoring outcome - Brain tissue oxygenation
Time Frame: First 7 days
|
Brain tissue oxygen (mmHg).
|
First 7 days
|
Monitoring outcome - PRx
Time Frame: First 7 days
|
Derived variables of cerebral elastance (Pressure reactivity index, PRx).
|
First 7 days
|
Pharmacological outcome - Concentration of IL1ra in brain tissue
Time Frame: First week
|
IL-1ra brain concentration (pg/ml), measured every 6 hours by cerebral microdialysis.
|
First week
|
Pharmacological outcome - Concentration of IL1ra in serum
Time Frame: First week
|
IL-1ra serum concentration (pg/ml), measured every 12 hours.
|
First week
|
Side effects of the IL1ra
Time Frame: First week + up to 12 months follow-up
|
To study any potential side-effect of the drug, both known and unknown.
|
First week + up to 12 months follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Adel Helmy, MA, MB BChir, FRCS, PhD, University of Cambridge
Publications and helpful links
General Publications
- Helmy A, Guilfoyle MR, Carpenter KL, Pickard JD, Menon DK, Hutchinson PJ. Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J Cereb Blood Flow Metab. 2014 May;34(5):845-51. doi: 10.1038/jcbfm.2014.23. Epub 2014 Feb 26.
- Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 Aug;5(8):629-40. doi: 10.1038/nri1664.
- Bullock MR, Lyeth BG, Muizelaar JP. Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies. Neurosurgery. 1999 Aug;45(2):207-17; discussion 217-20. doi: 10.1097/00006123-199908000-00001.
- Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, Bratton SL, Chesnut R, Harris OA, Kissoon N, Rubiano AM, Shutter L, Tasker RC, Vavilala MS, Wilberger J, Wright DW, Ghajar J. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017 Jan 1;80(1):6-15. doi: 10.1227/NEU.0000000000001432.
- Hyder AA, Wunderlich CA, Puvanachandra P, Gururaj G, Kobusingye OC. The impact of traumatic brain injuries: a global perspective. NeuroRehabilitation. 2007;22(5):341-53.
- Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006 Jan;147 Suppl 1(Suppl 1):S232-40. doi: 10.1038/sj.bjp.0706400.
- Singh N, Hopkins SJ, Hulme S, Galea JP, Hoadley M, Vail A, Hutchinson PJ, Grainger S, Rothwell NJ, King AT, Tyrrell PJ. The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. J Neuroinflammation. 2014 Jan 3;11:1. doi: 10.1186/1742-2094-11-1.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCTU0185
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traumatic Brain INjury
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
BrainScope Company, Inc.RecruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
-
Institut National de la Santé Et de la Recherche...Institut National de Recherche en Informatique et en AutomatiqueNot yet recruitingTBI (Traumatic Brain Injury)France
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
Queen Mary University of LondonCompleted
-
Northeastern UniversityBrandeis UniversityRecruitingTraumatic Brain Injury | Mild Traumatic Brain Injury | TBI | Moderate Traumatic Brain InjuryUnited States
Clinical Trials on Isotonic saline
-
Slagelse HospitalZealand University Hospital; Copenhagen University Hospital at Herlev; Holbaek... and other collaboratorsNot yet recruitingAsthma in Children | Bronchiolitis | Respiratory Disease | Acute Respiratory Infection | Viral Infection
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
Belfast Health and Social Care TrustUnknownBronchiectasisUnited Kingdom
-
Hospital Universitario Ramon y CajalFondo de Investigacion SanitariaTerminated
-
University of PittsburghCompleted
-
Regional Hospital HolstebroCompleted
-
Aalborg UniversityCompletedKnee Pain Chronic | Isotonic Saline | Hypertonic Saline | Healthy Eld HumanDenmark
-
Ospedale Misericordia e DolceCompletedContrast-Induced NephropathyItaly
-
Aalborg UniversityUniversity of Southern DenmarkCompleted